Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
Incyte Corporation
Herlev Hospital
Sumitomo Pharma America, Inc.
Herlev Hospital
Incyte Corporation
Duke University
Five Prime Therapeutics, Inc.